AR101561A1 - Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona - Google Patents
Nucleósidos de 2-cloro aminopirimidinona y pirimidina dionaInfo
- Publication number
- AR101561A1 AR101561A1 ARP150102625A ARP150102625A AR101561A1 AR 101561 A1 AR101561 A1 AR 101561A1 AR P150102625 A ARP150102625 A AR P150102625A AR P150102625 A ARP150102625 A AR P150102625A AR 101561 A1 AR101561 A1 AR 101561A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- independently
- group
- formula
- Prior art date
Links
- 229910052801 chlorine Inorganic materials 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000000460 chlorine Substances 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 8
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 150000001721 carbon Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000006413 ring segment Chemical group 0.000 abstract 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 abstract 1
- -1 -O-C1−8 alkyl Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ se selecciona de NH y N; la línea punteada (- - - -), en conjunto con la línea sólida a la que es paralela, representa un doble enlace opcional; R² se selecciona de oxo o NH₂, con la condición de que, cuando R² es oxo, R¹ es NH y el enlace representado por la línea punteada (- - - -), en conjunto con la línea sólida a la que es paralela, es un enlace sencillo; y con la condición de que, cuando R² es NH₂, R¹ es N y el enlace representado por la línea punteada (- - - -), en conjunto con la línea sólida a la que es paralela, es un enlace doble; R³ se selecciona del grupo de H, F, CH₂F, CHF₂, y CF₃; R⁵ se selecciona del grupo de CN, alquilo C₁₋₄ no sustituido, alquilo C₁₋₄ sustituido con 1, 2, ó 3 halógenos, alquilo C₁₋₄ sustituido con 1 sustituyente seleccionado de -S-CH₃ y -O-CH₃, alquenilo C₂₋₄, alquinilo C₂₋₄, cicloalquilo C₃₋₆ no sustituido, cicloalquilo C₃₋₆ sustituido por 1, 2, ó 3 sustituyentes seleccionados de F y CH₃; R⁴ se selecciona del grupo de H, -C(=O)R⁶, -C(=O)OR⁶, y -C(=O)NR⁶R⁷; R⁴ se selecciona del grupo de H, -C(=O)R⁶, -C(=O)OR⁶, y -C(=O)NR⁶R⁷; o c) R⁴ es un grupo de la fórmula (2), en donde: cada Y es O, S, NR, ⁺N(O)(R), N(O), ⁺N(O)(O), o N-NR₂; y W¹ y W², cuando se toman juntos, son -Y³(C(Rʸ)₂)₃Y³-; o uno de W¹ o W² junto con R⁴ es -Y³- y el otro de W¹ o W² es de fórmula (3); o W¹ y W² son cada uno, independientemente, un grupo de la fórmula (3), en donde: cada Y¹ es, independientemente, O, S, NR, ⁺N(O)(R), N(O), ⁺N(O)(O), o N-NR₂; cada Y² es independientemente un enlace, O, CR₂, -O-CR₂-, NR, ⁺N(O)(R), N(O), ⁺N(O)(O), N-NR₂, S, S-S, S(O), o S(O)₂; cada Y³ es un enlace sencillo; M1 es 0, 1, 2, ó 3; cada Rˣ es independientemente Rʸ o el compuesto de fórmula (4), en donde: cada M2a, M2b, y M2c es independientemente 0 ó 1; M2d es 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ó 12; cada Rʸ es independientemente H, F, Cl, Br, I, OH, R, -C(=Y¹)R, -C(=Y¹)O, -C(=Y¹)N(R)₂, -⁺N(R)₃, -SR, -S(O)R, -S(O)₂R, -S(O)(O), -S(O)₂(O), -OC(=Y¹)R, -OC(=Y¹)O, -OC(=Y¹)(N(R)₂), -SC(=Y¹)R, -SC(=Y¹)O, -SC(=Y¹)(N(R)₂), -N(R)C(=Y¹)R, -N(R)C(=Y¹)O, -N(R)C(=Y¹)N(R)₂, -SO₂NR², -CN, -N₃, -NO₂, -O, o W³; o cuando se toman juntos, dos Rʸ en el mismo átomo de carbono forman un anillo carbocíclico que tiene 3, 4, 5, 6, ó 7 átomos de carbono en el anillo; o cuando se toman juntos, dos Rʸ en el mismo átomo de carbono forman junto con el átomo de carbono un heterociclo que tiene 3, 4, 5, 6, ó 7 átomos de anillo en donde un átomo del anillo se selecciona de O ó N y todos los otros átomos de anillo son carbono; cada R es independientemente H, alquilo C₁₋₈, alquilo C₁₋₈ sustituido, alquenilo C₂₋₈, alquenilo C₂₋₈ sustituido, alquinilo C₂₋₈, alquinilo C₂₋₈ sustituido, arilo C₆₋₁₀, arilo C₆₋₁₀ sustituido, un heterociclo de 3 a 10 miembros, un heterociclo de 3 a 10 miembros sustituido, un heteroarilo de 5 a 12 miembros, un heteroarilo de 5 a 12 miembros sustituido, arilalquilo, arilalquilo sustituido, heteroarilalquilo, o heteroarilalquilo sustituido; y W³ es W⁴ o W⁵; W⁴ es R, -C(Y¹)Rʸ, -C(Y¹)W⁵, -SO₂Rʸ, o -SO₂W⁵; W⁵ se selecciona de fenilo, naftilo, un carbociclo C₃₋₈, o un heterociclo de 3 a 10 miembros, en donde W⁵ está independientemente sustituido con 0, 1, 2, 3, 4, 5, o 6 grupos Rʸ; cada R⁶ y R⁷ es independientemente H, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, carbociclilalquilo C₄₋₈, arilo C₆₋₁₀, arilo C₆₋₁₀ sustituido, heteroarilo de 5 a 10 miembros, heteroarilo de 5 a 10 miembros sustituido, -C(=O)alquilo C₁₋₈, -S(O)ₙ-alquilo C₁₋₈ o arilo-alquilo C₁₋₈; o R⁶ y R⁷ tomados junto con un nitrógeno al cual ambos están unidos forman un heterociclo de 3 a 7 miembros en donde cualquier átomo de carbono del anillo de dicho heterociclo se puede reemplazar opcionalmente con -O-, -S- o -NRᵃ-; y en donde cada alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈ o arilo-alquilo C₁₋₈ de cada R⁶ o R⁷ está, independientemente, opcionalmente sustituido con uno, dos, tres, o cuatro sustituyentes seleccionados de halo, hidroxi, CN, N₃, N(Rᵃ)₂ o ORᵃ; y en donde uno, dos, o tres de los átomos de carbono no terminales de cada dicho alquilo C₁₋₈ se pueden reemplazar opcionalmente con -O-, -S- o -NRᵃ-; o b) R⁴ es un grupo seleccionado de las fórmulas (5) y (6) en donde: R⁸ se selecciona de fenilo, 1-naftilo, 2-naftilo, un resto de fórmula (7) y (8); R⁹ se selecciona de H y CH₃; R¹⁰ se selecciona de H o alquilo C₁₋₆; R¹⁰ se selecciona de H o alquilo C₁₋₆; o R¹⁰ y R¹⁰, junto con el átomo de carbono al que están enlazados, forman un espirociclo de 3, 4, 5 ó 6 miembros en donde todos los átomos de anillo del espirociclo son carbono; o R¹⁰ y R¹⁰, junto con el átomo de carbono al que están enlazados, forman un espirociclo de 3, 4, 5 ó 6 miembros en donde 1 ó 2 de los átomos de anillo del espirociclo son seleccionados del grupo de O, S, y N, y todos los otros átomos de anillo del espirociclo son carbono; R¹¹ se selecciona de H, alquilo C₁₋₈, bencilo, cicloalquilo C₃₋₆, -CH₂-cicloalquilo C₃₋₆, -CH₂CH₂-S-C(O)-alquilo C₃₋₆, un resto de fórmula (9) y (10); R⁷ se selecciona de alquilo C₁₋₈, -O-alquilo C₁₋₈, bencilo, -O-bencilo, -CH₂-cicloalquilo C₃₋₆, y CF₃; o e) R⁴ y R⁴ se combinan para formar la estructura seleccionada de fórmulas (11) y (12).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040349P | 2014-08-21 | 2014-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101561A1 true AR101561A1 (es) | 2016-12-28 |
Family
ID=54066190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102625A AR101561A1 (es) | 2014-08-21 | 2015-08-14 | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9617295B2 (es) |
| EP (2) | EP3183261B1 (es) |
| JP (2) | JP6765364B2 (es) |
| KR (1) | KR102528928B1 (es) |
| CN (1) | CN106573954A (es) |
| AR (1) | AR101561A1 (es) |
| AU (1) | AU2015305593C1 (es) |
| BR (1) | BR112017003242A2 (es) |
| CA (1) | CA2958546C (es) |
| EA (1) | EA201790234A1 (es) |
| ES (1) | ES2808868T3 (es) |
| IL (1) | IL250426A0 (es) |
| MX (1) | MX2017002288A (es) |
| NZ (1) | NZ728707A (es) |
| SG (1) | SG11201700810SA (es) |
| TW (1) | TWI673283B (es) |
| WO (1) | WO2016028866A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2794627T1 (sl) | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
| PE20170698A1 (es) * | 2014-09-26 | 2017-06-05 | Riboscience Llc | Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| WO2018009623A1 (en) * | 2016-07-08 | 2018-01-11 | Atea Pharmaceuticals, Inc. | β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS |
| WO2019113462A1 (en) | 2017-12-07 | 2019-06-13 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| EP4431100A4 (en) * | 2021-11-12 | 2025-01-15 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| TW202400134A (zh) | 2022-03-15 | 2024-01-01 | 美商羅米醫療公司 | 用於治療疾病之化合物及方法 |
| WO2024016639A1 (zh) * | 2022-07-21 | 2024-01-25 | 华创合成制药股份有限公司 | 一种抗病毒感染的化合物及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (es) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| ES2141108T3 (es) | 1991-07-02 | 2000-03-16 | Inhale Inc | Metodo y dispositivo para proporcionar medicamentos en aerosol. |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| KR100905221B1 (ko) * | 2000-10-18 | 2009-07-01 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| HRP20120758T1 (hr) | 2007-01-12 | 2012-10-31 | Biocryst Pharmaceuticals, Inc. | Antiviralni nukleozidni analozi |
| WO2008141079A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| US8012941B2 (en) | 2008-04-23 | 2011-09-06 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| PL2480559T3 (pl) | 2009-09-21 | 2013-11-29 | Gilead Sciences Inc | Sposoby i związki pośrednie do wytwarzania analogów 11cyjanokarbanukleozydowych |
| JP5795766B2 (ja) | 2009-09-21 | 2015-10-14 | ギリード・サイエンシズ・インコーポレーテッド | 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体 |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| SG186831A1 (en) | 2010-07-19 | 2013-02-28 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| WO2012012776A1 (en) | 2010-07-22 | 2012-01-26 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
| US8877731B2 (en) * | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| SI2794627T1 (sl) * | 2011-12-22 | 2019-02-28 | Alios Biopharma, Inc. | Substituirani nukleozidi, nukleotidi in njihovi analogi |
| MX361460B (es) * | 2012-03-21 | 2018-12-06 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. |
| GB201220843D0 (en) * | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| TW201542578A (zh) * | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
| SG11201602595TA (en) * | 2013-10-11 | 2016-04-28 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
-
2015
- 2015-08-07 TW TW104125796A patent/TWI673283B/zh active
- 2015-08-14 AR ARP150102625A patent/AR101561A1/es unknown
- 2015-08-19 EA EA201790234A patent/EA201790234A1/ru unknown
- 2015-08-19 EP EP15760544.5A patent/EP3183261B1/en active Active
- 2015-08-19 WO PCT/US2015/045849 patent/WO2016028866A1/en not_active Ceased
- 2015-08-19 BR BR112017003242A patent/BR112017003242A2/pt not_active Application Discontinuation
- 2015-08-19 EP EP20180058.8A patent/EP3738969A1/en active Pending
- 2015-08-19 NZ NZ728707A patent/NZ728707A/en unknown
- 2015-08-19 JP JP2017508531A patent/JP6765364B2/ja active Active
- 2015-08-19 SG SG11201700810SA patent/SG11201700810SA/en unknown
- 2015-08-19 CN CN201580044979.5A patent/CN106573954A/zh active Pending
- 2015-08-19 ES ES15760544T patent/ES2808868T3/es active Active
- 2015-08-19 US US14/830,121 patent/US9617295B2/en active Active
- 2015-08-19 AU AU2015305593A patent/AU2015305593C1/en active Active
- 2015-08-19 CA CA2958546A patent/CA2958546C/en active Active
- 2015-08-19 MX MX2017002288A patent/MX2017002288A/es unknown
- 2015-08-19 KR KR1020177006312A patent/KR102528928B1/ko active Active
-
2017
- 2017-02-02 IL IL250426A patent/IL250426A0/en unknown
- 2017-02-24 US US15/441,561 patent/US9982006B2/en active Active
-
2018
- 2018-04-11 US US15/950,442 patent/US20180340004A1/en not_active Abandoned
- 2018-12-06 US US16/212,374 patent/US20190202852A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,536 patent/US20200157137A1/en not_active Abandoned
- 2019-09-10 US US16/565,888 patent/US20200087337A1/en not_active Abandoned
-
2020
- 2020-04-10 JP JP2020070958A patent/JP2020111608A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016028866A1 (en) | 2016-02-25 |
| JP6765364B2 (ja) | 2020-10-07 |
| EP3183261A1 (en) | 2017-06-28 |
| KR20170042643A (ko) | 2017-04-19 |
| CA2958546A1 (en) | 2016-02-25 |
| JP2017525699A (ja) | 2017-09-07 |
| JP2020111608A (ja) | 2020-07-27 |
| US20190202852A1 (en) | 2019-07-04 |
| MX2017002288A (es) | 2017-05-22 |
| EP3183261B1 (en) | 2020-06-17 |
| US20170327526A1 (en) | 2017-11-16 |
| CA2958546C (en) | 2020-06-23 |
| EP3738969A1 (en) | 2020-11-18 |
| KR102528928B1 (ko) | 2023-05-08 |
| CN106573954A (zh) | 2017-04-19 |
| SG11201700810SA (en) | 2017-03-30 |
| US20200157137A1 (en) | 2020-05-21 |
| AU2015305593C1 (en) | 2018-11-15 |
| US20200087337A1 (en) | 2020-03-19 |
| IL250426A0 (en) | 2017-03-30 |
| US9982006B2 (en) | 2018-05-29 |
| AU2015305593B2 (en) | 2018-05-17 |
| US9617295B2 (en) | 2017-04-11 |
| EA201790234A1 (ru) | 2017-07-31 |
| NZ728707A (en) | 2018-06-29 |
| TWI673283B (zh) | 2019-10-01 |
| US20160052953A1 (en) | 2016-02-25 |
| ES2808868T3 (es) | 2021-03-02 |
| US20180340004A1 (en) | 2018-11-29 |
| TW201619178A (zh) | 2016-06-01 |
| AU2015305593A1 (en) | 2017-02-23 |
| BR112017003242A2 (pt) | 2017-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR101280A1 (es) | Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| MX2016012984A (es) | Derivados indol para uso en medicina. | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR110405A1 (es) | Compuestos | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR097279A1 (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR104415A1 (es) | Compuestos antiestrogénicos derivados de cromeno | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR102256A1 (es) | Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi | |
| AR111814A1 (es) | Compuestos de formimidamida útiles contra microorganismos fitopatógenos | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |